Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation

Research output: Contribution to journalReviewResearchpeer-review

Standard

Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation. / Nielsen, Ole Haagen; Gubatan, John Mark; Kolho, Kaija-Leena; Streett, Sarah Elizabeth; Maxwell, Cynthia.

In: The Lancet, Vol. 403, No. 10433, 30.03.2024, p. 1291-1303.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Nielsen, OH, Gubatan, JM, Kolho, K-L, Streett, SE & Maxwell, C 2024, 'Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation', The Lancet, vol. 403, no. 10433, pp. 1291-1303. https://doi.org/10.1016/S0140-6736(24)00052-7

APA

Nielsen, O. H., Gubatan, J. M., Kolho, K-L., Streett, S. E., & Maxwell, C. (2024). Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation. The Lancet, 403(10433), 1291-1303. https://doi.org/10.1016/S0140-6736(24)00052-7

Vancouver

Nielsen OH, Gubatan JM, Kolho K-L, Streett SE, Maxwell C. Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation. The Lancet. 2024 Mar 30;403(10433):1291-1303. https://doi.org/10.1016/S0140-6736(24)00052-7

Author

Nielsen, Ole Haagen ; Gubatan, John Mark ; Kolho, Kaija-Leena ; Streett, Sarah Elizabeth ; Maxwell, Cynthia. / Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation. In: The Lancet. 2024 ; Vol. 403, No. 10433. pp. 1291-1303.

Bibtex

@article{57fcfa9eba094d06a0d5195defdd8c5b,
title = "Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation",
abstract = "Inflammatory bowel disease (IBD) affects reproductive planning due to psychological effects and mechanical problems related to surgery. Children of people with IBD have an increased risk of about 10% if one parent has IBD and up to 33% if both parents have IBD. The fertility of people with IBD is similar to the general population, but fertility might be reduced in individuals with active IBD, ileal pouch-anal anastomosis, or perianal Crohn's disease. Flaring disease during pregnancy increases complications, such as preterm birth. Thus, disease management with appropriate medications can optimise outcomes. As most medications have minimal fetal risks, people with IBD should be informed about the risks of stopping medications and the importance of maintaining remission. A period of disease remission is advisable before pregnancy and could reduce the risks for both the pregnant person and the fetus. Flexible endoscopy, intestinal ultrasound, and gadolinium-free magnetic resonance enterography are safe during pregnancy. We provide state-of-the-art knowledge on the basis of the latest evidence to ensure successful pregnancy outcomes in controlled IBD.",
author = "Nielsen, {Ole Haagen} and Gubatan, {John Mark} and Kaija-Leena Kolho and Streett, {Sarah Elizabeth} and Cynthia Maxwell",
note = "Copyright {\textcopyright} 2024 Elsevier Ltd. All rights reserved.",
year = "2024",
month = mar,
day = "30",
doi = "10.1016/S0140-6736(24)00052-7",
language = "English",
volume = "403",
pages = "1291--1303",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "10433",

}

RIS

TY - JOUR

T1 - Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation

AU - Nielsen, Ole Haagen

AU - Gubatan, John Mark

AU - Kolho, Kaija-Leena

AU - Streett, Sarah Elizabeth

AU - Maxwell, Cynthia

N1 - Copyright © 2024 Elsevier Ltd. All rights reserved.

PY - 2024/3/30

Y1 - 2024/3/30

N2 - Inflammatory bowel disease (IBD) affects reproductive planning due to psychological effects and mechanical problems related to surgery. Children of people with IBD have an increased risk of about 10% if one parent has IBD and up to 33% if both parents have IBD. The fertility of people with IBD is similar to the general population, but fertility might be reduced in individuals with active IBD, ileal pouch-anal anastomosis, or perianal Crohn's disease. Flaring disease during pregnancy increases complications, such as preterm birth. Thus, disease management with appropriate medications can optimise outcomes. As most medications have minimal fetal risks, people with IBD should be informed about the risks of stopping medications and the importance of maintaining remission. A period of disease remission is advisable before pregnancy and could reduce the risks for both the pregnant person and the fetus. Flexible endoscopy, intestinal ultrasound, and gadolinium-free magnetic resonance enterography are safe during pregnancy. We provide state-of-the-art knowledge on the basis of the latest evidence to ensure successful pregnancy outcomes in controlled IBD.

AB - Inflammatory bowel disease (IBD) affects reproductive planning due to psychological effects and mechanical problems related to surgery. Children of people with IBD have an increased risk of about 10% if one parent has IBD and up to 33% if both parents have IBD. The fertility of people with IBD is similar to the general population, but fertility might be reduced in individuals with active IBD, ileal pouch-anal anastomosis, or perianal Crohn's disease. Flaring disease during pregnancy increases complications, such as preterm birth. Thus, disease management with appropriate medications can optimise outcomes. As most medications have minimal fetal risks, people with IBD should be informed about the risks of stopping medications and the importance of maintaining remission. A period of disease remission is advisable before pregnancy and could reduce the risks for both the pregnant person and the fetus. Flexible endoscopy, intestinal ultrasound, and gadolinium-free magnetic resonance enterography are safe during pregnancy. We provide state-of-the-art knowledge on the basis of the latest evidence to ensure successful pregnancy outcomes in controlled IBD.

U2 - 10.1016/S0140-6736(24)00052-7

DO - 10.1016/S0140-6736(24)00052-7

M3 - Review

C2 - 38458222

VL - 403

SP - 1291

EP - 1303

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10433

ER -

ID: 384828571